{"id":57747,"date":"2023-07-14T19:04:15","date_gmt":"2023-07-14T17:04:15","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/infinity-pharmaceuticals-announces-stockholder-approval-of-merger-with-mei-pharma\/"},"modified":"2023-07-14T19:04:15","modified_gmt":"2023-07-14T17:04:15","slug":"infinity-pharmaceuticals-announces-stockholder-approval-of-merger-with-mei-pharma","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/infinity-pharmaceuticals-announces-stockholder-approval-of-merger-with-mei-pharma\/","title":{"rendered":"Infinity Pharmaceuticals Announces Stockholder Approval of Merger with MEI Pharma"},"content":{"rendered":"
\n

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (\u201cInfinity\u201d), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming drug candidate, announced that, based on a preliminary vote count, its stockholders have adopted the previously announced merger agreement providing for the merger with MEI Pharma, Inc. (\u201cMEI\u201d) at the special meeting of Infinity stockholders held earlier today (the \u201cSpecial Meeting\u201d).<\/p>\n

\nThe transaction remains subject to approval by MEI stockholders.<\/p>\n

\nFinal voting results for the Special Meeting will be disclosed on Form 8-K filed by Infinity with the U.S. Securities and Exchange Commission.<\/p>\n

\nAbout Infinity Pharmaceuticals<\/b><\/p>\n

\nInfinity Pharmaceuticals, Inc. (Nasdaq: INFI) is a clinical-stage biotechnology company developing eganelisib (IPI-549), a potential first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which is designed to address a fundamental biologic mechanism of immune suppression in cancer in multiple clinical studies. For more information on Infinity, please refer to Infinity\u2019s website at www.infi.com<\/a>.<\/p>\n

\nImportant Information about the Merger and Where to Find It<\/b><\/p>\n

\nThis communication relates to a proposed transaction between Infinity and MEI. In connection with the proposed merger, MEI filed with the United States Securities and Exchange Commission (the \u201cSEC\u201d) a registration statement on Form S-4 that includes a joint proxy statement of MEI and Infinity (the \u201cJoint Proxy Statement\/Prospectus\u201d) that also constitutes a prospectus of MEI. The registration statement on Form S-4 was declared effective by the SEC on June 6, 2023. MEI and Infinity have each filed and mailed the Joint Proxy Statement\/Prospectus to their respective stockholders. INVESTORS AND MEI\u2019S AND INFINITY\u2019S RESPECTIVE STOCKHOLDERS ARE URGED TO READ THE JOINT PROXY STATEMENT\/PROSPECTUS IN ITS ENTIRETY AND ANY OTHER DOCUMENTS FILED BY EACH OF MEI AND INFINITY WITH THE SEC IN CONNECTION WITH THE PROPOSED MERGER OR INCORPORATED BY REFERENCE THEREIN BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED MERGER AND THE PARTIES TO THE PROPOSED MERGER. Investors and stockholders may obtain a free copy of the Joint Proxy Statement\/Prospectus and other documents containing important information about MEI and Infinity from the SEC\u2019s website at www.sec.gov<\/a>. MEI and Infinity make available free of charge at www.meipharma.com<\/a> and www.infi.com<\/a>, respectively (in the \u201cInvestors\u201d and \u201cInvestors\/Media\u201d sections, respectively), copies of materials they file with, or furnish to, the SEC.<\/p>\n

\nParticipants in the Solicitation<\/b><\/p>\n

\nMEI, Infinity and their respective directors, executive officers and certain employees and other persons may be deemed to be participants in the solicitation of proxies from the stockholders of MEI and Infinity in connection with the proposed merger. Securityholders may obtain information regarding the names, affiliations and interests of MEI\u2019s and Infinity\u2019s directors and executive officers in the Joint Proxy Statement\/Prospectus which may be obtained free of charge from the SEC\u2019s website at www.sec.gov<\/a>, MEI\u2019s investor website at https:\/\/www.meipharma.com\/investors<\/a> and Infinity\u2019s investor website at https:\/\/investors.infi.com\/<\/a>.<\/p>\n

\nNo Offer or Solicitation<\/b><\/p>\n

\nThis communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.<\/p>\n

\nCautionary Statement Regarding Forward-Looking Statements<\/b><\/p>\n

\nCertain statements contained in this filing may be considered forward-looking statements within the meaning of the federal securities law. Such statements are based upon current plans, estimates and expectations of the management of MEI and Infinity that are subject to various risks and uncertainties that could cause actual results to differ materially from such statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Words such as \u201canticipate,\u201d \u201cexpect,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cbelieve,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cplan,\u201d \u201ccould,\u201d \u201ccontinue,\u201d \u201ctarget,\u201d \u201ccontemplate,\u201d \u201cestimate,\u201d \u201cforecast,\u201d \u201cguidance,\u201d \u201cpredict,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpursue,\u201d \u201clikely,\u201d and words and terms of similar substance used in connection with any discussion of future plans, actions or events identify forward-looking statements. All statements, other than historical facts, including statements regarding: the expected timing of the closing of the proposed merger; the ability of the parties to complete the proposed merger considering the various closing conditions; the expected benefits of the proposed merger, including estimations of anticipated cost savings and cash runway; the competitive ability and position of the combined company; the potential, safety, efficacy, and regulatory and clinical progress of the combined company\u2019s product candidates, including the anticipated timing for initiation of clinical trials and release of clinical trial data and the expectations surrounding potential regulatory submissions, approvals and timing thereof; the sufficiency of the combined company\u2019s cash, cash equivalents and short-term investments to fund operations; and any assumptions underlying any of the foregoing, are forward-looking statements. Important factors that could cause actual results to differ materially from MEI\u2019s and Infinity\u2019s plans, estimates or expectations could include, but are not limited to: (i) the risk that the proposed merger may not be completed in a timely manner or at all, which may adversely affect MEI\u2019s and Infinity\u2019s businesses and the price of their respective securities; (ii) uncertainties as to the timing of the consummation of the proposed merger and the potential failure to satisfy the conditions to the consummation of the proposed merger, including obtaining stockholder and regulatory approvals; (iii) the proposed merger may involve unexpected costs, liabilities or delays; (iv) the effect of the announcement, pendency or completion of the proposed merger on the ability of MEI or Infinity to retain and hire key personnel and maintain relationships with customers, suppliers and others with whom MEI or Infinity does business, or on MEI\u2019s or Infinity\u2019s operating results and business generally; (v) MEI\u2019s or Infinity\u2019s respective businesses may suffer as a result of uncertainty surrounding the proposed merger and disruption of management\u2019s attention due to the proposed merger; (vi) the outcome of any legal proceedings related to the proposed merger or otherwise, or the impact of the proposed merger thereupon; (vii) MEI or Infinity may be adversely affected by other economic, business, and\/or competitive factors; (viii) the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement and the proposed merger; (ix) restrictions during the pendency of the proposed merger that may impact MEI\u2019s or Infinity\u2019s ability to pursue certain business opportunities or strategic transactions; (x) the risk that MEI or Infinity may be unable to obtain governmental and regulatory approvals required for the proposed merger, or that required governmental and regulatory approvals may delay the consummation of the proposed merger or result in the imposition of conditions that could reduce the anticipated benefits from the proposed merger or cause the parties to abandon the proposed merger; (xi) risks that the anticipated benefits of the proposed merger or other commercial opportunities may otherwise not be fully realized or may take longer to realize than expected; (xii) the impact of legislative, regulatory, economic, competitive and technological changes; (xiii) risks relating to the value of MEI shares to be issued in the proposed merger; (xiv) the risk that integration of the proposed merger post-closing may not occur as anticipated or the combined company may not be able to achieve the benefits expected from the proposed merger, as well as the risk of potential delays, challenges and expenses associated with integrating the combined company\u2019s existing businesses; (xv) exposure to inflation, currency rate and interest rate fluctuations, as well as fluctuations in the market price of MEI\u2019s and Infinity\u2019s traded securities; (xvi) the impact of the COVID-19 pandemic on MEI\u2019s and Infinity\u2019s industry and individual companies, including on counterparties, the supply chain, the execution of clinical development programs, access to financing and the allocation of government resources; (xvii) final data from pre-clinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; (xviii) costs and delays in the development and\/or U.S. Food and Drug Administration (\u201cFDA\u201d) approval, or the failure to obtain such approval, of the combined company\u2019s product candidates; (xix) regulatory authorities may not agree with the design or results of clinical studies and as a result future clinical studies may be subject to holds; (xx) uncertainties or differences in interpretation in clinical trial results; (xxi) the combined company\u2019s inability to maintain or enter into, and the risks resulting from dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any product candidates; and (xxii) the ability of MEI or Infinity to protect and enforce intellectual property rights; and (xxiii) the unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or outbreak of war or hostilities, as well as MEI\u2019s and Infinity\u2019s response to any of the aforementioned factors. Additional factors that may affect the future results of MEI and Infinity are set forth in their respective filings with the SEC , including the section entitled \u201cRisk Factors\u201d in the Registration Statement on Form S-4 that was declared effective by the SEC on June 6, 2023 and each of MEI\u2019s and Infinity\u2019s most recently filed Annual Reports on Form 10-K, subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC, which are available on the SEC\u2019s website at www.sec.gov<\/a>. See in particular MEI\u2019s Annual Report on Form 10-K for the fiscal year ended June 30, 2022 in Part I, Item 1A, \u201cRisk Factors,\u201d and Infinity\u2019s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, in Part I, Item 1A, \u201cRisk Factors.\u201d The risks and uncertainties described above and in the SEC filings cited above are not exclusive and further information concerning MEI and Infinity and their respective businesses, including factors that potentially could materially affect their respective businesses, financial conditions or operating results, may emerge from time to time. Readers are urged to consider these factors carefully in evaluating these forward-looking statements, and not to place undue reliance on any forward-looking statements. Any such forward-looking statements represent management\u2019s reasonable estimates and beliefs as of the date of this press release. While MEI and Infinity may elect to update such forward-looking statements at some point in the future, they disclaim any obligation to do so, other than as may be required by law, even if subsequent events cause their views to change.<\/p>\n

\nThis press release contains hyperlinks to information that is not deemed to be incorporated by reference.<\/p>\n

Contacts<\/b> <\/p>\n

\nInfinity Contact
\n
<\/b>Melissa Hackel
\n
Tel: 617-453-1117<\/p>\n

\nMorrow Sodali, LLC
\n
<\/b>Tel: (800) 662-5200
\n
INFI@info.morrowsodali.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (\u201cInfinity\u201d), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming drug candidate, announced that, based on a preliminary vote count, its stockholders have adopted the previously announced merger agreement providing for the merger with MEI Pharma, Inc. (\u201cMEI\u201d) at the special meeting of Infinity stockholders … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-57747","6":"format-standard","7":"category-industry"},"yoast_head":"\nInfinity Pharmaceuticals Announces Stockholder Approval of Merger with MEI Pharma - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/infinity-pharmaceuticals-announces-stockholder-approval-of-merger-with-mei-pharma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Infinity Pharmaceuticals Announces Stockholder Approval of Merger with MEI Pharma - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass.–(BUSINESS WIRE)–Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (\u201cInfinity\u201d), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming drug candidate, announced that, based on a preliminary vote count, its stockholders have adopted the previously announced merger agreement providing for the merger with MEI Pharma, Inc. (\u201cMEI\u201d) at the special meeting of Infinity stockholders ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/infinity-pharmaceuticals-announces-stockholder-approval-of-merger-with-mei-pharma\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-14T17:04:15+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/infinity-pharmaceuticals-announces-stockholder-approval-of-merger-with-mei-pharma\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/infinity-pharmaceuticals-announces-stockholder-approval-of-merger-with-mei-pharma\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Infinity Pharmaceuticals Announces Stockholder Approval of Merger with MEI Pharma\",\"datePublished\":\"2023-07-14T17:04:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/infinity-pharmaceuticals-announces-stockholder-approval-of-merger-with-mei-pharma\\\/\"},\"wordCount\":1824,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/infinity-pharmaceuticals-announces-stockholder-approval-of-merger-with-mei-pharma\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/infinity-pharmaceuticals-announces-stockholder-approval-of-merger-with-mei-pharma\\\/\",\"name\":\"Infinity Pharmaceuticals Announces Stockholder Approval of Merger with MEI Pharma - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2023-07-14T17:04:15+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/infinity-pharmaceuticals-announces-stockholder-approval-of-merger-with-mei-pharma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/infinity-pharmaceuticals-announces-stockholder-approval-of-merger-with-mei-pharma\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/infinity-pharmaceuticals-announces-stockholder-approval-of-merger-with-mei-pharma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Infinity Pharmaceuticals Announces Stockholder Approval of Merger with MEI Pharma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Infinity Pharmaceuticals Announces Stockholder Approval of Merger with MEI Pharma - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/infinity-pharmaceuticals-announces-stockholder-approval-of-merger-with-mei-pharma\/","og_locale":"en_US","og_type":"article","og_title":"Infinity Pharmaceuticals Announces Stockholder Approval of Merger with MEI Pharma - Pharma Trend","og_description":"CAMBRIDGE, Mass.–(BUSINESS WIRE)–Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (\u201cInfinity\u201d), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming drug candidate, announced that, based on a preliminary vote count, its stockholders have adopted the previously announced merger agreement providing for the merger with MEI Pharma, Inc. (\u201cMEI\u201d) at the special meeting of Infinity stockholders ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/infinity-pharmaceuticals-announces-stockholder-approval-of-merger-with-mei-pharma\/","og_site_name":"Pharma Trend","article_published_time":"2023-07-14T17:04:15+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/infinity-pharmaceuticals-announces-stockholder-approval-of-merger-with-mei-pharma\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/infinity-pharmaceuticals-announces-stockholder-approval-of-merger-with-mei-pharma\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Infinity Pharmaceuticals Announces Stockholder Approval of Merger with MEI Pharma","datePublished":"2023-07-14T17:04:15+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/infinity-pharmaceuticals-announces-stockholder-approval-of-merger-with-mei-pharma\/"},"wordCount":1824,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/infinity-pharmaceuticals-announces-stockholder-approval-of-merger-with-mei-pharma\/","url":"https:\/\/pharma-trend.com\/en\/infinity-pharmaceuticals-announces-stockholder-approval-of-merger-with-mei-pharma\/","name":"Infinity Pharmaceuticals Announces Stockholder Approval of Merger with MEI Pharma - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2023-07-14T17:04:15+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/infinity-pharmaceuticals-announces-stockholder-approval-of-merger-with-mei-pharma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/infinity-pharmaceuticals-announces-stockholder-approval-of-merger-with-mei-pharma\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/infinity-pharmaceuticals-announces-stockholder-approval-of-merger-with-mei-pharma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Infinity Pharmaceuticals Announces Stockholder Approval of Merger with MEI Pharma"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/57747","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=57747"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/57747\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=57747"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=57747"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=57747"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}